ProtoKinetix Releases Third in a Series of Scientific Update Videos

MARIETTA, Ohio–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/privateplacement?src=hash” target=”_blank”gt;#privateplacementlt;/agt;–ProtoKinetix, Incorporated (www.protokinetix.com)
(the “Company” or “ProtoKinetix”) (OTCQB:PKTX)
announces the launch of the third in a series of informational videos by
the Principal Investigators in each field currently being tested.

The third video is an update on the testing in the University of British
Columbia. UBC will be testing AAGP™ ability to enhance the recovery from
storage as well as the survival and efficacy of engraftment of
hematopoietic stem cells, a technical hurdle in cell-based therapies for
bone marrow transplantation and cancer therapy.

The goal will be to determine whether AAGP™ enhances the ex vivo
survival and maintenance of these valuable stem cells. The study is
being conducted under the direction of principal investigator Dr. Kelly
McNagny, Professor, Faculty of Medicine, Department of Medical Genetics.

Dr.
Kelly McNagny Video

Dr.
Kelly McNagny Bio

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and
patented a family of hyper stable, potent glycopeptides (AAGP®) that
enhance both engraftment and protection of transplanted cells used in
regenerative medicine. Due to the results achieved over the last four
years of testing, the University of Alberta has begun Phase 1 human
clinical trials. Additional studies will be expanded to include whole
organ transplantation and all therapies that are being developed
globally to date; cancer, diabetes, retinal degeneration, and cardiac
muscle repair.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward
looking statements” within the meaning of Section 27A of the Securities
Act of 1933 (the “Securities Act”) and Section 21E of the Securities
Exchange Act of 1934 (the “Exchange Act”).
All statements, other
than statements of historical facts, included herein concerning, among
other things, planned capital expenditures, future cash flows and
borrowings, pursuit of potential acquisition opportunities, our
financial position, business strategy and other plans and objectives for
future operations, are forward looking statements. These forward looking
statements are identified by their use of terms and phrases such as
“may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,”
“achievable,” “anticipate,” “will,” “continue,” “potential,” “should,”
“could,” and similar terms and phrases.
Although we believe that
the expectations reflected in these forward looking statements are
reasonable, they do involve certain assumptions, risks and uncertainties
and are not (and should not be considered to be) guarantees of future
performance.
Among these risks are those set forth in a Form 10-K
filed on March 9, 2018. It is important that each person reviewing this
release understand the significant risks attendant to the operations of
ProtoKinetix. ProtoKinetix disclaims any obligation to update any
forward-looking statement made here.

Contacts

Clarence E. Smith
President and Chief Executive Officer
Telephone:
304-299-5070
Email: [email protected]
Twitter:
@ProtoKinetix

error: Content is protected !!